Finance Watch: AbCellera, 4DMT, Nanobiotix IPOs Bring In $775m Combined

Post-ASH Offerings Also Bring In Big Bucks

Public Company Edition: Lilly’s COVID-19 antibody partner AbCellera launched one of the biggest IPOs of 2020, bringing in $483m. Also, two more SPACs went public; Sinovac, Biocryst and Kura Oncology arranged large financings; and Viatris plans post-merger layoffs.

Finance Watch

AbCellera Biologics Inc., 4D Molecular Therapeutics LLC (4DMT) and Nanobiotix SA launched initial public offerings on 10 and 11 December that brought in a combined $774.8m. The AbCellera offering alone, which grossed $483m from the sale of 24.2 million shares at $20 each, may end up being the largest biopharmaceutical company IPO in the US this year.

Underwriters for the offering still have an option to sell another 3.6 million shares within the next 30 days to...

More from Financing

More from Business

Quick Listen: Scrip’s Five Must-Know Things

 
• By 

In this week's episode: US policies in spotlight at BIO; Lilly’s Verve acquisition; UroGen’s bladder cancer approval; Ireland’s biopharma talent; and Korea proposes new AI R&D project.

Asia Deal Watch: SunRock, Escugen Collaborate On CCR9-Targeted ADC

 

Axcelead/Lotte Biologics/Kanaph and NextCure/Simcere also unveil ADC-focused pacts, plus deals involving Avata/Oceanus, GSK/Bharat Biotech, Cullinan/Genrix and more.

Defying Gravity: Five Drugs That Surpassed Their Sales Forecasts

 

Many assets outperform their pre-launch sales predictions despite the frequent overestimation of forecasts within the industry. In this article, Scrip highlights several such assets and the factors that influenced their predictions.